Laid off from B. Braun.

What B. Braun layoffs have meant for employees

CAPS, the pharmacy services company B. Braun took on with its 1997 purchase of McGaw Inc., decided in 2026 to leave 503B sterile compounding, the large-batch side of its work. The move was part of a "strategic refocus on its core operations and long-term sustainability," B. Braun's spokesperson, Alli Longenhagen, told WFMZ. CAPS's website listed Upper Macungie and Phoenix as its only 503B sites, and both drew closing notices that year, a Pennsylvania notice for the two Upper Macungie buildings and a June letter to Arizona for Phoenix. If your job was at either site, CAPS is ending that work, and Quva bought a range of the medications it made, so it's worth looking at the options B. Braun has described.

In the Lehigh Valley those options came in two steps. The first, in June, pointed people toward jobs elsewhere in B. Braun. The second was B. Braun's September 8 release, in which the two companies said Quva had bought a range of CAPS's medications; Quva expected to start introducing selected products in phases later in 2026, then expand its offerings over the following six months. A $20 million expansion of B. Braun's own Hanover Township plant, also in the Lehigh Valley, would create at least 200 full-time jobs over three years and retain 1,704 existing positions, the Pennsylvania governor's office said in September 2025. If you have one of the Quva offers in WFMZ's September report and are also considering an opening inside B. Braun, you can compare when each job would start with the date your CAPS job ends, keeping in mind that the Quva roles B. Braun described were at its New Jersey plant. If you're among the staff kept through the wind-down, which B. Braun said would last through year's end, your last day may come well after September 30, the date B. Braun gave for the last shipments.

Phoenix's notice staggered its cuts over several months. The redeployment and the Quva offers B. Braun's spokesperson described were for the Lehigh Valley site. If you're at the Phoenix facility, ABC15 reported the layoff dates from CAPS's letter to Arizona.

California's 2023 notices are the older part of this story, and they came from two different places. B. Braun Medical's notices were for permanent layoffs at the Irvine plant on McGaw Avenue, per EDD's WARN report, a former McGaw Medical plant that, in the Orange County Business Journal's telling, came to B. Braun with McGaw in 1997, the same deal that brought in CAPS. That puts all five filings in our tracker at operations B. Braun took on in that one deal. The plant makes intravenous solutions and bags for hospitals, and B. Braun was finishing a $500 million, seven-year modernization of the Irvine campus in 2025, the Business Journal reported. Later, the plant was hiring, with 2,000 employees by August 2025 after it added 200 to meet demand during an IV shortage that followed Hurricane Helene. CAPS's 2023 San Diego notice was for its Dunbrook Road site, one of three FDA-registered outsourcing facilities the San Diego Business Journal counted for CAPS in 2022. By June 2026, CAPS's website listed two 503B sites.

The October announcement on Interventional Systems follows the same logic in a different business, with B. Braun citing "core businesses" in Cardiac Interventions Today's account, much as the CAPS exit was framed around "core operations." The five filings in our tracker are CAPS's and B. Braun Medical's, and they sit in California, Arizona and Pennsylvania. For CAPS and B. Braun Medical workers in those three states, we cover unemployment claims for Pennsylvania, Arizona and California on separate pages.